Tech Transfer eNews Blog
Industry-Sponsored Research Management

Recro Pharma licenses novel neuromuscular pain drugs from Cornell


By Jesse Schwartz
Published: July 12th, 2017

Recro Pharma, a developer of therapeutics for hospital settings, has acquired exclusive global rights to two neuromuscular blocking agents (NMBs) and a chemical reversal agent from Cornell University.

The licensed drugs may significantly reduce patients’ pain and post-procedure time in the operating room and could lead to valuable cost savings for hospitals and ambulatory surgical centers.

“This transaction strengthens our portfolio, with the addition of several novel compounds which have the potential to be significant contributors within the surgical anesthesia space and complement our existing pipeline of hospital/acute care pain products,” says Gerri Henwood, president and CEO of Recro Pharma.

Under the terms of the deal, Recro will make an upfront payment of $350,000 to Cornell, with a $5 million milestone payment for each U.S. regulatory approval of the technologies and $3 million for each EU approval, in addition to royalties on sales.

Brian Kelly, director of the Center for Technology Licensing at Cornell, comments, “We look forward to working with Recro Pharma Inc. to commercialize a series of proprietary neuromuscular blocking agents that may benefit patients and the medical community.”

Sources: Recro Pharma and Seeking Alpha

DON’T MISS THESE ARTICLES IN THE JULY ISSUE OF INDUSTRY-SPONSORED RESEARCH MANAGEMENT:

  • IP concerns shouldn’t be a deal breaker in open innovation partnerships.
  • Sponsors, research managers encouraged to consider incentives for data reproducibility.
  • UGA’s strategies bring progress in goal to boost industry sponsorships.
  • Philips, Pitt collaboration features internships, open innovation.
  • Chicago’s new Connectory will facilitate research deals with IoT focus.
  • Industry sponsors a focus of Penn State’s new ‘industryXchange’ series.

CLICK HERE TO SUBSCRIBE AND SAVE $100 WITH OUR CHARTER OFFER!

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment